These new Policy Principles build upon SWHR’s 2019 principles, now accounting for changes in the health care value assessment landscape that specifically impact women.
BlogThe text of the Consolidated Appropriations Act, 2022 (H.R. 2471) includes emergency funding for COVID-19 and Ukraine, and other provisions.
BlogThe Food and Drug Administration (FDA) Advisory Committee has made history for women by recommending approval of Sprout Pharmaceuticals’ twice-rejected female libido drug Flibanserin.
BlogThis blog summarizes the state of disparities in biomedical research and how they might be addressed.
EventJoin the Healthcare Businesswomen’s Association for an in-depth exploration of the current landscape of women’s health in the United States, […]
EventJoin the National Academies of Sciences, Engineering, and Medicine for a virtual symposium on March 16, 2022 that will highlight […]
BlogDr. Diana Bianchi gave remarks on NICHD’s role in advancing research in pregnant and lactating populations during an October meeting of the Coalition to Advance Maternal Therapeutics (CAMT).
BlogSWHR remembers former SWHR Board member Bruce McEwen, PhD, who passed away on January 2, 2020.
BlogSWHR released the outputs of its two-day workshop “Achieving Meaningful Subgroup Data in Clinical Trial Design and Development: Scientific Approaches and Considerations.”
BlogColorectal cancer is the third most common cancer in women behind lung and breast — and not just among the elderly. In fact, colorectal cancer diagnoses are becoming increasingly common in individuals younger than 50.